Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis: An Open-label, Multicenter, Randomized, Controlled Trial: NoVa

NCT06464510 Phase 3 RECRUITING

The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.

Details

Lead sponsor	Hospital do Coracao
Phase	Phase 3
Status	RECRUITING
Enrolment	2800
Start date	2024-11-21
Completion	2027-09

Conditions

• Septic Shock

Interventions

• Early Vasopressin
• Norepinephrine and Vasopressin for Rescue

Primary outcomes

• All-cause mortality or renal replacement therapy — 28 days
  Composite of all-cause mortality or renal replacement therapy within 28 days after randomization.

Countries

Brazil